EU Panel Backs Lenalidomide- and Pomalidomide-Based Triplets for Myeloma

March 29, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted positive opinions to 2 triplet regimens with immunomodulatory agents (IMiDs) for patients with multiple myeloma. The first 3-drug treatment is lenalidomide in combination with bortezomib and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for stem cell transplant … (leggi tutto)